Loading
MAPK1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signalling cascade initiated by activated KIT and KITLG/SCF.
CIViC holds 5 clinical evidence items and 1 assertion across 3 variants, naming Erlotinib and WZ4002. Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes clinical 0.19, affected pathway 0.86, literature 0.99, genetic association 0.08, somatic mutation 0.95). IntOGen calls it a driver in 5 cohorts (4 activating, 1 loss-of-function), covering Cervical Squamous Cell Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma.
In plain words · MAPK1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
MAPK1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade.
No product in this corpus aims at MAPK1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA MAPK1: RNA low tissue specificity; high antibody staining in 24 normal tissues; highest cancer staining colorectal cancer (12 of 12 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma, Cervical cancer, Hepatocellular carcinoma, Breast cancer (all types), Skin cancer (all types), Lung cancer (all types), Leukaemia); Open Targets associates it with 1 specific cancer type at or above 0.5 (cervical squamous cell carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P28482; CIViC gene MAPK1; IntOGen MAPK1; Human Protein Atlas MAPK1 tissue; Open Targets ENSG00000100030 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Owaki et al, Biochem. Biophys. Res. Commun, 1992, "Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs". Source.
Sources: HGNC HGNC:6871 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P28482 (protein name, function text, keywords and locations (REST API)); CIViC gene MAPK1 (5 evidence items, 1 assertions, 3 variants; diseases: Head And Neck Squamous Cell Carcinoma, Lung Non-small Cell Carcinoma, Cancer (GraphQL API, CC0)); Open Targets ENSG00000100030 (association with cancer (MONDO_0004992) 0.82; per-cancer scores at or above 0.5: cervical cancer 0.52, skin cancer 0.52, breast cancer 0.54, lung cancer 0.51 (GraphQL API, CC0)); IntOGen MAPK1 (driver in 5 cohorts (Act 4, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signalling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Location: Cytoplasm, cytoskeleton, spindle; Nucleus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm (UniProt). Locus 22q11.22 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Bone marrow, Endometrium, Heart muscle, Kidney, Nasopharynx, Oral mucosa, Ovary.
Medium only: skin cancer.
HPA MAPK1 tissue · HPA MAPK1 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MAPK1" OR ABSTRACT:"MAPK1" OR TITLE:"mitogen-activated protein kinase 1" OR ABSTRACT:"mitogen-activated protein kinase 1" OR TITLE:"Mitogen-activated protein kinase 1" OR ABSTRACT:"Mitogen-activated protein kinase 1" OR TITLE:"ERK2" OR ABSTRACT:"ERK2" OR TITLE:"p41mapk" OR ABSTRACT:"p41mapk" OR TITLE:"MAPK2" OR ABSTRACT:"MAPK2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAPK1, not a curated reading list.